PAUL SAGAN - 28 Apr 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Director
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 28 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 02 May 2022, 16:42:45 UTC
Previous filing: 15 Oct 2021
Next filing: 14 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+703		$0.000000	703	28 Apr 2022	Direct	F1
holding	MRNA	Common Stock						14,951	28 Apr 2022	By: Erwin Park LLC	F2
holding	MRNA	Common Stock						76,452	28 Apr 2022	By: The Chatham Trust	F2
holding	MRNA	Common Stock						370,407	28 Apr 2022	By: The Paul Sagan Revocable Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-703	-100%	$0.000000^*	0	28 Apr 2022	Common Stock	703	$0.000000	Direct	F1, F3
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+5,415		$0.000000	5,415	28 Apr 2022	Common Stock	5,415	$142.52	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Erwin Park LLC is an investment vehicle owned by the Reporting Person's children. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3	The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F4	This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.